Skip to main content

Table 1 Baseline characteristics of the study population

From: Prognostic value of rising mean platelet volume during hospitalization in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

Variable

Survivors (n = 370)

Non-survivors (n = 110)

P-value

Age (year)

58 ± 11

68 ± 13

<  0.001

Female n (%)

80 (22)

37 (34)

0.010

Hypertension n (%)

151 (41)

63 (57)

0.002

Diabetes mellitus n (%)

78 (21)

37 (34)

0.007

Hyperlipidemia n (%)

76 (21)

24 (22)

0.772

Current smoking n (%)

168 (45)

40 (36)

0.098

Previous CAD n (%)

64 (17)

27 (25)

0.089

Prior stroke/TIA n (%)

5 (1)

9 (8)

<  0.001

Killip class ≥2 n (%)

21 (6)

20 (18)

<  0.001

Multi-vessel disease n (%)

132 (36)

57 (52)

0.002

GP IIb/IIIa inhibitors n (%)

107 (29)

37 (34)

0.343

Medication at discharge

 Beta-blocker n (%)

319 (86)

82 (73)

0.004

 Statin n (%)

312 (84)

85 (77)

0.086

 ACE-I/ARB n (%)

315 (85)

76 (69)

<  0.001

 DAPT n (%)

365 (99)

107 (97)

0.322

Infarct related artery

0.097

 LAD n (%)

170 (46)

50 (46)

 

 Cx n (%)

57 (15)

8 (7)

 

 RCA n (%)

129 (35)

49 (45)

 

 Others n (%)

14 (4)

3 (2)

 

Outcomes

 30-day death n (%)

0 (0)

19 (17)

<  0.001

 Stroke n (%)

7 (2)

5 (5)

0.118

 HF admission n (%)

7 (2)

15 (14)

<  0.001

 Myocardial reinfarction n (%)

30 (8)

8 (7)

0.776

 TVR n (%)

45 (12)

11 (10)

0.535

  1. HF heart failure, CAD coronary artery disease, TIA transient ischemic attack, ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, TVR; target vessel revascularization, DAPT dual antiplatelet therapy